CEO Executive AssistantMarket access strategy pharma CEO responsibilities have grown substantially as reimbursement environments have tightened globally. In the United States, the Inflation Reduction Act has introduced direct Medicare price negotiation. In Europe, joint clinical assessment requirements under HTA regulation are reshaping evidence dossiers. In emerging markets, access programs increasingly require government engagement at ministerial levels. For pharma CEOs, market access is no longer a commercial function that runs downstream of clinical development. It is a strategic capability that must be designed into programs from early development.
The time management challenge is substantial. Market access spans evidence generation strategy, payer engagement, government affairs, pricing decisions, and launch sequencing – across multiple geographies with different rules. CEOs who try to be involved in all of it lose strategic altitude. Those who disengage entirely find market access becoming a bottleneck to commercial performance.
Redefining the CEO’s Market Access Role
Your role in market access is not to negotiate with individual payers or to design value dossiers. It is to ensure three things: that market access strategy is integrated with clinical development from the beginning, that your organization has the right capability and leadership to execute across geographies, and that you are personally engaged on the decisions and relationships where CEO involvement creates disproportionate value.
The most common gap is the first of these. Pharma companies that treat market access as a post-approval commercial activity consistently underperform those that design for access at the protocol level. This means your clinical evidence generation plan must be built with payer evidence requirements in mind, not just regulatory requirements. It means your pricing assumptions must be validated against real-world reimbursement constraints before you commit to commercial forecasts. It means your CMO, Chief Commercial Officer, and Head of Market Access need to be working together continuously, not sequentially.
Your job is to build that integration. It requires setting expectations, creating joint planning processes, and reviewing the alignment regularly.
Where CEO Time in Market Access Creates the Most Value
National Payer Relationships in Priority Markets
In several key markets – Germany, France, Japan, and others – the relationship between the pharmaceutical company’s most senior leadership and national health authority officials or major payer representatives carries real weight. This is not about CEO involvement in routine negotiations. It is about establishing, early, that your company’s leadership is engaged and serious about market access and patient access commitments.
Identify the one to two markets where CEO-level payer or HTA engagement would be most valuable. In Germany, a relationship with GKV or G-BA leadership during your early HTA preparation may matter. In Japan, engagement with MHLW and PMDA at CEO level is standard practice for innovative products and expected. In the United States, engagement with major PBM executives for a significant launch can support formulary positioning.
Build these engagements into your international travel cadence. Two to three market access-focused meetings per international trip, combined with other business objectives in those markets, is an efficient allocation.
Pricing Strategy at the CEO Level
Drug pricing decisions are among the highest-consequence and most time-intensive responsibilities a pharma CEO navigates. They require CEO involvement because they cannot be resolved at a functional level: they sit at the intersection of clinical evidence, competitive positioning, payer strategy, government relations, patient access commitments, and board expectations.
Establish a formal pricing governance process in your company that convenes when you are entering the 18-to-24-month window before a major launch. This process should surface clear pricing scenarios with explicit assumptions, trade-offs between price level and access breadth, and a recommended strategy. The CEO chairs or personally reviews the final pricing recommendation before it becomes company policy.
Do not let pricing decisions be made purely by commercial optimization. The reputational and regulatory dimensions of pricing decisions require executive oversight that extends beyond revenue modeling.
Launch Sequencing Decisions
In which countries do you launch first? The sequencing decision affects reference pricing, payer negotiations in subsequent markets, and the speed with which patients in different geographies access your therapy. It is a strategic decision with financial, clinical, and ethical dimensions.
Your commercial and market access teams should present a structured launch sequencing analysis. The CEO makes the final call when sequencing involves meaningful trade-offs – for example, a faster U.S. launch at high price versus a broader European launch at lower price that provides real-world evidence but sets international reference prices earlier.
Building Market Access Into Development Planning
The most efficient use of CEO time in market access is upstream: ensuring that clinical development is generating the evidence that payers actually require. This means your market access team has a voice in:
- Trial design: Are the comparators, endpoints, and patient populations aligned with payer evidence requirements in your priority markets?
- Real-world evidence strategy: Is there a plan for post-approval evidence generation that supports formulary maintenance and label expansions?
- Patient-reported outcomes: Are patient-relevant endpoints included in trials in a way that supports HTA dossiers?
Build this into your regular pipeline review cadence process so that market access strategy is reviewed alongside clinical and regulatory strategy at every stage gate, not as an afterthought when the clinical program is complete.
Managing Geographic Complexity Without Losing Focus
Pharma CEOs running global portfolios face the temptation to engage deeply in multiple geographic market access situations simultaneously. Resist this. The CEO’s direct engagement creates value in a small number of high-priority situations; it does not scale across 30 markets.
Build a geographic tier framework for market access:
Tier 1 markets (typically US, top EU5, Japan, China for global companies) receive CEO attention at defined moments: launch sequencing decisions, CEO-level payer or HTA meetings, and any government pricing intervention that requires executive response.
Tier 2 and 3 markets are managed by your regional commercial leadership and market access teams, with CEO visibility through quarterly commercial reporting. You engage in Tier 2 markets only when there is a specific strategic question or a relationship opening that requires your level.
Your Head of Global Market Access should maintain a live view of access status across markets, with clear flags for the CEO on situations that need your input. Review this at your quarterly commercial operations review, not through ad hoc status requests.
Government Affairs and Policy: The Market Access Adjacency
Market access strategy cannot be separated from government affairs in most major markets. IRA implementation, European HTA coordination, and emerging market pricing policies are shaped by policy processes that require pharmaceutical industry engagement at the senior level.
CEOs who engage in industry trade associations – EFPIA, PhRMA, IFPMA – are investing in the policy environment that their market access teams operate within. This is a legitimate use of CEO time: typically two to four board or committee meetings per year, plus occasional direct government engagement on significant policy developments.
The management challenge is ensuring this external policy engagement connects back to your internal market access strategy. Your government affairs team should brief you before major policy engagements so that your positions are consistent with your company’s specific market access priorities, and they should debrief you after on any insights that affect your strategy.
The board reporting pharma function should capture market access risks and milestones as a standing board agenda item, ensuring directors have visibility into access dynamics that affect commercial projections.
Organizing Your Market Access Leadership Team
Market access spans health economics, outcomes research, payer engagement, government affairs, and pricing strategy. This is too broad for one person to own fully. The most effective organizations have a Head of Global Market Access with deep payer and HTA expertise, supported by regional market access leads with accountability for specific geographies.
The CEO’s interface is through the Head of Global Market Access (or equivalent) and the Chief Commercial Officer. Monthly one-on-ones with your market access leader, focused on the top strategic priorities and any pending decisions, keep you calibrated without drawing you into day-to-day payer management.
Build an annual market access strategy review into your planning cycle. This is a two to three hour session where your market access leadership presents the current access landscape, the evidence gaps that threaten access in priority markets, and the investment requirements to close them. This review shapes your evidence generation and commercial investment priorities for the coming year.
Conclusion
Market access strategy pharma CEO leadership requires a clear separation between the strategic decisions and relationships that justify CEO time and the execution work that belongs to a capable market access organization. Your highest-value interventions are designing market access into development early, owning pricing governance, maintaining select payer and government relationships, and leading launch sequencing decisions across markets. Everything else compounds in value when you have built the right team and created the right processes – and costs you strategic altitude when you do not.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.